Trial · NCT05131828
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
NCT05131828, Phase 2, Completed, Cambridge University Hospitals NHS Foundation Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy. Trials, record NCT05131828. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05131828
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
- NCT number
- NCT05131828
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 70 participants, actual
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Conditions
- Multiple Sclerosis
- Interventions
- Metformin and clemastine in combination, Placebo
- First posted
- 2021-11-23
- Last updated
- 2025-12-11
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the change in the P100 latency of the full-field visual evoked potential (VEP) between baseline and week 26 for each affected eye of participants | Baseline to week 26 | |
| Secondary | The change in MF-VEP latency, between baseline and week 26, for those eyes with delayed latency at baseline | Baseline to week 26 | |
| Secondary | The change in lesional MTR, between baseline and week 26, for the lesions stratified by location | Baseline to week 26 | |
| Secondary | The change in lesional MTR between baseline and week 26, for the lesions stratified by tissue-specific cohort baseline lesional MTR values | Baseline to week 26 | |
| Secondary | Adverse events and withdrawals attributable to metformin and/or clemastine | Baseline to week 28 | |
| Other | The change, between baseline and week 26, in the N75 and N145 latencies of the full-field VEP | Baseline to week 26 | |
| Other | The change in full field VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline | Baseline to week 26 | |
| Other | The change in MF-VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline | Baseline to week 26 | |
| Other | The change in the number of letters read (and the corresponding LogMAR score) on the Sloan 100%, 2.5% and 1.25% acuity charts, between baseline and week 28 | Baseline to week 28 | |
| Other | The change in colour vision between baseline and week 28 | Baseline to week 28 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41361285 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Antisaccade Task | Other outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05131828
GET https://conductscience.org/api/trials/v1/NCT05131828/registered